Zhangya Dental's initial public offering on the ChiNext board has been accepted by the Shenzhen Stock Exchange. This marks the company's second attempt to enter the capital market after a previous filing in 2023 fell through. From 2023 to 2025, the company's revenue grew from 648 million yuan to 938 million yuan, with a compound annual growth rate of approximately 20%. In 2025, the number of cases reached 206,700, surpassing Align Technology's Invisalign's 181,600 cases, propelling the company to second place in the industry. The domestic invisible orthodontics market has shifted from a "duopoly" to a "three-way stalemate," with ANGELALIGN holding 37.75%, Zhangya at 28.86%, and Align Technology at 24.82%, collectively controlling over 90% of the market share.
Scrutinizing the financial details reveals issues that are more glaring than the achievements. The unit price of Zhangya Dental's classic aligners is only 32.36 to 34.53 yuan each, which is less than half the price of ANGELALIGN's standard version, which is about 75 yuan per unit. Zhangya's gross margin stands at 55.34%, significantly lower than the over 60% levels seen at ANGELALIGN and Align Technology. R&D investment as a percentage of revenue has decreased annually from 9.03% to 6.1%, while advertising and marketing expenses have increased from 70.75 million yuan to 87.38 million yuan over the same period. Third-party payments account for nearly 30% of total collections, a patent lawsuit involving nearly 10 million yuan remains unresolved, and a "time bomb" is hidden within the valuation adjustment mechanism agreement. In essence, Zhangya Dental has secured the second spot in the industry through a "low-price-for-scale" strategy, but the sustainability of this low-price approach, the depth of its technological moat, and the standardization of its internal controls are all shaky foundations.
Low Prices Drive Scale
Zhangya Dental's core strategy is precisely "small profits but quick turnover." From 2023 to 2025, the unit price of its classic aligners was 34.53 yuan, 34.44 yuan, and 32.36 yuan, respectively, showing a declining trend. During the same period, ANGELALIGN's standard version was priced at about 75 yuan per unit, and Invisalign is even more expensive. Zhangya's pricing strategy is very clear: use a price less than half that of the giants to capture consumers who are budget-conscious but still want invisible orthodontic treatment. In the end market, Invisalign is quoted at 30,000 to 50,000 yuan, ANGELALIGN at 20,000 to 30,000 yuan, and Zhangya below 20,000 yuan. This strategy has indeed been effective. In 2020, Zhangya's market share was only 8.6%, far behind ANGELALIGN (41%) and Invisalign (41.4%). Five years later, Zhangya has jumped to second place with a 28.86% market share, achieving a compound annual growth rate of nearly 20%, the fastest among leading industry players. From 8.6% to 28.86%, Zhangya has used low prices to carve out a niche, pulling invisible orthodontics from a "high-end luxury" to a "mass-affordable" price range. However, the cost of this low-price model is equally evident. In 2025, Zhangya's gross margin was 55.34%. Although it improved from 52.67% in 2023, it still lags significantly behind the over 60% gross margins of ANGELALIGN and Align Technology. This means that for every 100 yuan of products sold, Zhangya retains 5 to 10 yuan less in gross profit than the giants. In an industry considered "profitable," Zhangya's profit margin is far lower than external expectations. More critically, is there a ceiling for this low-price strategy? With prices already compressed to 32 yuan per unit, how much room is left for further decline? In 2025, Zhangya attempted to significantly lower prices to grab market share, but with limited results, indicating that the marginal benefits of price wars in the invisible orthodontics field are diminishing. Are customers acquired through low prices loyal enough? If cheaper new brands emerge, will these customers leave again? These are questions Zhangya has not answered in its prospectus, but investors will surely ask.
Another concern involves the investment by Straumann. In October 2025, the international dental giant Straumann Group made a strategic investment in Zhangya, holding a 5.95% stake. Both parties announced joint development on next-generation orthodontic platforms and invisible aligner technology. While Straumann's endorsement has indeed enhanced Zhangya's recognition in the international market, with products now in over 50 countries and regions, the low equity stake suggests Straumann's involvement is merely financial investment plus strategic cooperation, with a low likelihood of deep engagement in Zhangya's operations. Ultimately, whether Zhangya's globalization can truly succeed depends on its own team and capabilities, not just on Straumann's reputation.
Heavy Marketing, Light R&D
Zhangya Dental's resource allocation direction reveals a worrying signal. From 2023 to 2025, the company's R&D expenses were 58.5 million yuan, 53.04 million yuan, and 57.25 million yuan, respectively, with R&D investment as a percentage of revenue decreasing annually from 9.03% to 6.75% and then to 6.1%. During the same period, selling expenses were 207 million yuan, 247 million yuan, and 247 million yuan, with advertising and marketing expenses at 70.75 million yuan, 82.7 million yuan, and 87.38 million yuan, respectively, increasing year by year. Over three years, total advertising and marketing expenses reached 241 million yuan, while total R&D investment was only 169 million yuan. The money spent on advertising is 1.4 times that of R&D investment. The prospectus explains this as follows: first, airline advertisements targeting middle- and high-income groups; second, a Disney IP authorization for co-branded products in children's and adolescent orthodontic appliances, with royalty payments based on sales. The Disney IP licensed products are used for aligner packaging and related peripherals, directly targeting the blue ocean market of early pediatric orthodontics. Airline ads plus Disney co-branding, spending over 87 million yuan a year, is a significant investment among invisible orthodontics companies. However, the core competitiveness of a medical product should be technology and clinical data, not IP co-branding. An industry analyst pointedly noted that Zhangya's persistent high marketing spending and IP co-branding strategy is essentially a "passive defensive choice under growth pressure." Due to its relatively weak channel penetration and professional academic accumulation among core doctors, the company has to compensate for its B-end channel deficiencies through mass brand exposure. This model, on one hand, squeezes the space for R&D investment, and on the other hand, fails to build a brand moat based on medical professional attributes. Simply put, consumers might be attracted by a Disney co-branding, but ultimately, it is the doctor who fits the aligners for patients. Whether the doctor recognizes your technology is the key determinant of repeat purchase rates. Compare this with ANGELALIGN's path: ANGELALIGN uses dual-material technology and a diversified product line to cover different consumer levels, with fast response times for medical plans and deep channel penetration among doctors. Zhangya uses advertising and IP to reach consumers, while ANGELALIGN uses technology and services to lock in doctors. Which path is more sustainable? In an industry with strong medical attributes like invisible orthodontics, the answer is self-evident.
Internal Control Chaos and Legal Risks
Furthermore, Zhangya Dental's prospectus reveals a series of internal control and legal issues, the most direct being the problem of third-party payments. From 2023 to 2025, the company's third-party payments accounted for 30.51%, 29.84%, and 28.67% of total collections, respectively, nearly 30%. The company explains that this is due to expanding into small and medium-sized dental clinics at the county and district level, which are small in scale and sometimes use third-party payments based on their own funding arrangements. However, this explanation fails to reassure regulators and investors. In IPO reviews, a high proportion of third-party payments is typically seen as a sign of weak financial internal controls, as it increases the difficulty of revenue recognition and the risk of fraudulent transactions. A third-party payment ratio of nearly 30% is at a relatively high level among companies preparing to go public. More egregiously, from 2023 to 2024, Zhangya's subsidiary, Guangzhou Sesame, had employees using personal WeChat to collect training fees before transferring them to the company's bank account. This involved 242,800 yuan in 2023 and 1,500 yuan in 2024. Although the amounts are small, such practices expose a serious internal control loophole. A company preparing for listing cannot even manage the compliance of its collection channels, allowing personal WeChat to serve as a collection tool, which is a major taboo in financial audits. Fortunately, Guangzhou Sesame was deregistered in September 2024. A patent lawsuit involving over 10 million yuan is a bigger concern. On May 27, 2026, Hangzhou Shuyaqi filed a lawsuit in the Beijing Intellectual Property Court against Zhangya Dental and its three subsidiaries, alleging patent infringement, seeking 10 million yuan in damages plus reasonable expenses for rights protection. Zhangya argues that the patent in question had already expired in October 2024 and that the plaintiff's qualification is flawed, asserting that it will not restrict the company's production and operations. However, the outcome of the judicial ruling is uncertain. A loss in court would directly impact the company's performance, and more seriously, it could shake the trust of cooperative medical institutions in the company's technological originality, thereby affecting the stability of channel cooperation. The valuation adjustment mechanism agreement is another "time bomb" in the prospectus. Although specific terms are not disclosed in detail, such agreements typically trigger a repurchase clause if the IPO fails or performance targets are not met. If Zhangya's listing process encounters setbacks or future performance falls short of expectations, the valuation adjustment mechanism could impose significant financial pressure on the company. Additionally, Zhangya has a somewhat tainted past. In 2022, it was fined 450,000 yuan by the Shanghai Market Supervision Bureau for recruiting 400 Xiaohongshu bloggers to create fake promotions, none of whom had actually used the product. The same year, it published an unapproved medical device advertisement on the "Xinyang" WeChat public account, comparing it with other types of aligners, violating the Advertising Law, and was fined 1.03 million yuan. Although this history is in the past, it indicates that the company has previously stumbled in marketing compliance.
Marketing and Promotion Consume 31% of Total Funds Raised
The allocation of the 901 million yuan in funds raised is also noteworthy: 396 million yuan for capacity expansion, 122 million yuan for R&D center upgrades, 283 million yuan for marketing and promotion, and 100 million yuan for replenishing working capital. Marketing and promotion account for 31% of the total funds raised, more than double the 13% allocated for R&D center upgrades. This ratio indicates that Zhangya still prioritizes "market grabbing" over "building a moat" in the short term. However, in a technology-driven, doctor-led industry, whether this priority is reasonable remains to be tested over time. Zhangya Dental's IPO story begins with a classic "comeback" narrative: from a mere 8.6% market share, far behind the two giants, to jumping to second place in the industry five years later, driven by a low-price strategy, differentiated products, and heavy marketing. This achievement is indeed impressive in the domestic invisible orthodontics industry, and the capital market is willing to give such a growth story a valuation. However, the challenges of the second half are far more severe than the first. The profit margin of the low-price model is being squeezed, the trend of declining R&D investment as a percentage of revenue needs to be reversed, internal control loopholes must be fully plugged, and the potential risks of the patent lawsuit and the valuation adjustment mechanism need to be resolved. More importantly, Zhangya needs to build a genuine channel barrier among doctors. Advertising and Disney IP can attract consumers, but invisible orthodontics is a strongly medical industry where the final decision to purchase lies with the doctor. Without the professional recognition of doctors, even the best marketing can only generate one-time sales, not sustained repeat purchases. The ceiling for the invisible orthodontics industry is high. According to a report by Biaodian Information, the global market for orthodontic appliances was 13.8 billion U.S. dollars in 2025, with expectations to exceed 16 billion U.S. dollars by 2030. The penetration rate in the Chinese market is currently far lower than that of developed countries, indicating significant long-term growth potential. However, the ultimate winner in this market will not be the one with the largest marketing budget, but the one with the most solid technology, the most stable channels, and the brand most trusted by doctors. Whether Zhangya Dental can transition from second place to first depends on its ability to shift its strategic focus from "low-cost volume grabbing" to "technology-driven moat building" after going public. If it cannot make this turn, its position as the industry's second-place player may not be secure.
Comments